Lamond Megan K, Chetwynd Andrew J, Salama Alan D, Oni Louise
Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Department of Biochemistry and Systems Biology, Centre for Proteome Research, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
J Clin Lab Anal. 2024 Apr;38(7):e25032. doi: 10.1002/jcla.25032. Epub 2024 Mar 25.
Kidney disease is fairly unique due to the lack of symptoms associated with disease activity, and it is therefore dependent on biological monitoring. Dried biofluids, particularly dried capillary blood spots, are an accessible, easy-to-use technology that have seen increased utility in basic science research over the past decade. However, their use is yet to reach the kidney patient population clinically or in large-scale discovery science initiatives. The aim of this study was to systematically evaluate the existing literature surrounding the use of dried biofluids in kidney research.
A systematic literature review was conducted using three search engines and a predefined search term strategy. Results were summarised according to the collection method, type of biofluid, application to kidney disease, cost, sample stability and patient acceptability.
In total, 404 studies were identified and 67 were eligible. In total, 34,739 patients were recruited to these studies with a skew towards male participants (> 73%). The majority of samples were blood, which was used either for monitoring anti-rejection immunosuppressive drug concentrations or for kidney function. Dried biofluids offered significant cost savings to the patient and healthcare service. The majority of patients preferred home microsampling when compared to conventional monitoring.
There is an unmet need in bringing dried microsampling technology to advance kidney disease despite its advantages. This technology provides an opportunity to upscale patient recruitment and longitudinal sampling, enhance vein preservation and overcome participation bias in research.
由于缺乏与疾病活动相关的症状,肾脏疾病相当独特,因此依赖于生物学监测。干生物流体,特别是干毛细血管血斑,是一种易于获取、使用方便的技术,在过去十年中,其在基础科学研究中的应用越来越广泛。然而,它们在临床上或大规模发现科学计划中尚未应用于肾脏患者群体。本研究的目的是系统评价围绕干生物流体在肾脏研究中应用的现有文献。
使用三个搜索引擎和预定义的搜索词策略进行系统的文献综述。根据收集方法、生物流体类型、在肾脏疾病中的应用、成本、样本稳定性和患者可接受性对结果进行总结。
共识别出404项研究,其中67项符合条件。这些研究共招募了34739名患者,其中男性参与者占多数(>73%)。大多数样本是血液,用于监测抗排斥免疫抑制药物浓度或肾功能。干生物流体为患者和医疗服务节省了大量成本。与传统监测相比,大多数患者更喜欢在家中进行微量采样。
尽管干微量采样技术具有优势,但将其用于推进肾脏疾病研究仍存在未满足的需求。这项技术为扩大患者招募和纵向采样、加强静脉保护以及克服研究中的参与偏倚提供了机会。